LifeMD (LFMD) Q2 Revenue Rises 23%

LifeMD (NASDAQ:LFMD) reported mixed Q2 2025 results, with GAAP revenue growing 23% year-over-year to $62.2 million but missing analyst estimates by $4.1 million, and an EPS loss of $0.06 below expectations. Despite strong performance in its telehealth segment, which saw 30% revenue growth and a 560% increase in Adjusted EBITDA, management significantly cut full-year 2025 guidance across all major metrics, including total revenue to $250-$255 million and Adjusted EBITDA to $27-$29 million, citing challenges within its Rex MD men's health brand. This indicates specific segment execution issues and revised outlooks overshadowing otherwise robust core business expansion.

Analysis

LifeMD's (LFMD) second-quarter 2025 results present a conflicting picture of strong underlying operational growth overshadowed by a significant cut to forward guidance. While total revenue grew a robust 23% year-over-year to $62.2 million, it fell short of analyst estimates by $4.1 million, and the GAAP EPS loss of $0.06 was wider than the consensus forecast. The core telehealth segment remains the primary growth engine, with revenue surging 30% and its adjusted EBITDA increasing an impressive 560%. The company also demonstrated improved cost discipline, narrowing its GAAP net loss to $2.9 million from $7.7 million a year prior and generating over $8 million in operating cash flow. However, these positive operational metrics are undermined by management's decision to lower full-year 2025 guidance across all major metrics, now projecting total revenue of $250-$255 million and adjusted EBITDA of $27-$29 million. This revision is explicitly attributed to challenges in the Rex MD men's health brand, stemming from both business execution and regulatory complexity, introducing significant uncertainty into the company's near-term trajectory. Minor gross margin compression to 88% from 90% and ongoing reliance on the volatile GLP-1 medication market further compound the risk profile, despite promising but nascent expansions into behavioral and women's health.

Key Decisions for Investors

• Investors should weigh the strong operational momentum and profitability in the core telehealth segment against the significant uncertainty created by the full-year guidance cut, which signals material issues in the Rex MD brand.
• It is critical to monitor for any stabilization or further deterioration within the Rex MD men's health segment, as its performance is the primary driver behind the revised, weaker annual forecast.
• Consider the company's valuation in light of both the lowered earnings outlook and the substantial external risks tied to the regulatory environment and supply chain for GLP-1 weight-loss drugs.
• Track the revenue contribution from new verticals like behavioral and women's health, as successful execution in these areas could provide future growth catalysts and de-risk the business from its current challenges.